Rilotumumab companion diagnostic - Dako

Drug Profile

Rilotumumab companion diagnostic - Dako

Latest Information Update: 27 Nov 2014

Price : $50

At a glance

  • Originator Dako A/S
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 24 Nov 2014 No development reported - Clinical-Phase-Unknown for Cancer (Diagnosis) in Europe (unspecified route)
  • 24 Nov 2014 No development reported - Clinical-Phase-Unknown for Cancer (Diagnosis) in USA (unspecified route)
  • 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top